Trial Profile

Phase 2 clinical study of BMC128

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 28 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BMC 128 (Primary)
Indications Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma
Focus Therapeutic Use

23 May 2024 According to an Evogene media release, company is is now preparing for advancing to Phase 2 of BMC128 clinical trial, and already conducted a pre-IND meeting with the FDA, aiming to initiate Phase 2 in 2025.
23 Dec 2022 New trial record
21 Dec 2022 According to a Biomica media release, the company announced the signing of a definitive agreement for a $20 million financing round and proceeds will be used to advance this trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com